Trial Profile
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Tinengotinib (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colon cancer; Head and neck cancer; HER2 negative breast cancer; Mesothelioma; Peritoneal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors TransThera Biosciences
- 28 Dec 2023 Planned End Date changed from 30 Dec 2021 to 28 Feb 2024.
- 07 Dec 2023 According to a TransThera Biosciences media release, data from this study were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting.
- 07 Dec 2023 Results (N=36, cut off : October 1, 2023) presented in a TransThera Biosciences media release.